1. Introduction {#sec1}
===============

HIV infection in the absence of therapy is almost invariably fatal with few exceptions, but the introduction of combination antiretroviral therapy (ART) or highly active antiretroviral therapy (HAART) resulted in a dramatic decline in morbidity and mortality that has significantly changed the course of acquired HIV infection \[[@B1]\]. Approximately 35 million people worldwide are living with HIV and an estimated 15% to 30% are coinfected with hepatitis C virus (HCV) \[[@B2], [@B3]\], although in Thailand the prevalence of HCV coinfection with HIV has been reported as 7.8% \[[@B4]\]. Several studies have reported that HIV induced immunosuppression accelerates the natural history of HCV-related liver disease, and coinfected patients are 3- to 5-fold more likely to develop cirrhosis \[[@B5], [@B6]\]. Nevirapine (NVP), a nonnucleoside reverse transcriptase inhibitor (NNRTI), is frequently used in the HAART regimen for HIV-infected patients in resource limited settings despite the high risk of hepatotoxicity which occurs in approximately 12--15% of HIV- and HIV/HCV-coinfected patients \[[@B7]--[@B9]\].

HIV/HCV-coinfected patients are more likely to develop hepatotoxicity caused by HAART than HIV-monoinfected individuals, and HIV/HCV is associated with a 2--10-fold change of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) values above the upper level of normality after starting HAART, compared with HIV infection alone \[[@B10]\]. This is supported by studies that show that HCV is associated with a 2.46 increased relative risk (RR) for liver enzyme elevation (5 × upper limit of normal) \[[@B11]\] and that grades 3-4 liver enzyme elevation was detected in 20.8% of HIV/HCV-coinfected patients who continuously use NVP \[[@B12]\].

NVP hepatotoxicity is believed to be caused by two mechanisms: an early onset reaction characterized by skin reactions and elevated ALT/AST that occurs within the first two to three weeks of treatment \[[@B13]--[@B15]\] and a delayed onset that normally starts some 4-5 months after commencement of treatment \[[@B15], [@B16]\]. While the mechanism of hepatotoxicity remains poorly characterized, NVP metabolites such as 12-OH-NVP and quinone methide have been strongly implicated in the process \[[@B17], [@B18]\] and evidence for the metabolic activation of NVP through the detection of mercapturates in urine has been previously presented \[[@B19]\].

The early diagnosis of liver toxicity in patients undergoing long term treatment with NVP is critical as the condition can be lethal, and currently this is generally assessed by evaluation of alanine transaminase (ALT) levels \[[@B20]\]. This study aimed to use a proteomic analysis to identify possible biomarkers that are more specific to NVP toxicity than ALT in serum and urine fraction of patients with liver toxicity due to long term nevirapine use.

2. Methods {#sec2}
==========

2.1. Patients and Samples {#sec2.1}
-------------------------

### 2.1.1. Study Design and Participants {#sec2.1.1}

The patients included in the study consisted of 18 patients monoinfected with HIV and 13 patients coinfected with HIV and HCV who were being followed up at Maharaj Nakorn Chiang Mai Hospital. Additional five healthy individuals were recruited as controls. All patients received a HAART regimen containing NVP for at least four months. The study was approved by the Research Ethics Committee 2, Faculty of Medicine, Chiang Mai University (RIH-12-985-FB), and the Human Experimentation Committee, Research Institute for Health Sciences (RIHES), Chiang Mai University (4/55). Written informed consent was obtained from all participants.

Blood (10 mL each) and urine samples were obtained on the day of scheduled patient follow-up. Serum samples were prepared and screened for aspartate aminotransferase (AST), alanine transaminase (ALT), hepatitis B surface antigen (HBS-Ag), hepatitis B surface antibody (anti-HBS), anti-hepatitis-C antibodies (anti-HCV), and HIV virus antibody (anti-HIV). All serum and urine samples were stored at −80°C until analysis.

Participants with HIV/HCV with high ALT were eligible to participate if they had received a HAART regimen containing NVP for at least four months, have positive anti-HCV, have positive anti-HIV, were negative for HBS-Ag, were positive/negative for anti-HBS, and have serum ALT more than 1.25-fold of upper normal limit.

Participants with HIV/HCV with normal ALT were eligible to participate if they received a HAART regimen containing NVP for at least four months, have positive anti-HCV, have positive anti-HIV, were negative for HBS-Ag, were positive/negative for anti-HBS, and have serum ALT 0--40 U/L.

Participants with HIV monoinfection with high ALT were eligible to participate if they received a HAART regimen containing NVP for at least four months, have positive anti-HIV, have negative anti-HCV, were negative for HBS-Ag, were positive/negative for anti-HBS, and have serum ALT more than 1.25-fold of upper normal limit.

Participants with HIV monoinfection with normal ALT were eligible to participate if they received a HAART regimen containing NVP for at least four months, have positive anti-HIV, have negative anti-HCV, were negative for HBS-Ag, were positive/negative for anti-HBS, and have serum ALT 0--40 U/L.

The exclusion criteria included positive anti-HBsAg, negative anti-HCV in HIV/HCV coinfection, and less than four months of NVP treatment.

### 2.1.2. Sample Preparation {#sec2.1.2}

Urine samples were thawed at room temperature and centrifuged at 17,000 ×g for 15 min at room temperature to sediment cellular fragments. The supernatants were transferred into new 50 mL tubes and 2 volumes of cold acetone (−20°C) were added to each tube. The tubes were vortexed and subsequently incubated at −20°C overnight after which the samples were centrifuged for 15 minutes at 13,000 ×g. The protein pellets were dissolved in 0.5% SDS and the protein concentration was determined by the Lowry method \[[@B21]\]. Serum samples were diluted 1 : 10 with sterile nano water prior to protein measurement.

Protein samples from serum and urine were subsequently pooled into five groups, namely, HIV/HCV-coinfected patients with high ALT (group 1), HIV/HCV-coinfected patients with normal ALT (group 2), HIV-monoinfected patients with high ALT (group 3), HIV-monoinfected patients with normal ALT (group 4), and healthy individuals (Ctl).

### 2.1.3. Sub-10 kDa Peptidome Analysis {#sec2.1.3}

Approximately 240 *μ*g of pooled proteins from serum or urine was applied directly onto a Nanosep 10 K ultrafiltration device (Pall Life Sciences, Pall Corporation, Port Washington, NY) and the sub-10 kDa fraction removed for protein quantitation by the Lowry assay \[[@B21]\]. A total of 10 *μ*g of protein was transferred into a new tube and the volume adjusted to 10 *μ*L with 10 mM ammonium bicarbonate. The proteins were reduced with 10 mM dithiothreitol in 10 mM ammonium bicarbonate at room temperature for 1 hr and subsequently alkylated with 100 mM iodoacetamide in 10 mM ammonium bicarbonate at room temperature in the dark for 1 hr. Samples were digested with 10 ng trypsin in 50% acetonitrile/10 mM ammonium bicarbonate at room temperature for 3 hrs. The samples were dried under vacuum until the final volume was 10 *μ*L. Then the sample volume was adjusted to 15 *μ*L with 0.1% FA and subjected to LC-MS/MS exactly as described previously \[[@B22]\].

### 2.1.4. Two-Dimensional Gel Electrophoresis (2-DE) and Liquid Chromatography-Mass Spectrometry Analysis {#sec2.1.4}

Approximately 60 *μ*L of each of the pooled serum samples was taken and processed to deplete albumin using the ProteoExtract Albumin removal kit (Merck KGaA, Darmstadt, Germany) according to the manufacturers\' recommendations and protein concentrations were determined as described previously. Two-dimensional gel electrophoresis and LC-MS/MS analysis were performed essentially as described previously \[[@B23]\]. Briefly, 200 *μ*g of each pooled albumin depleted fraction was mixed with 340 *μ*L of rehydration buffer (8 M urea, 4% CHAPS, 0.001% bromophenol blue, and 3 mM dithiothreitol) containing 1% 3--10 NL IPG buffer. Samples were loaded onto 18 cm IPG strips with pH range of 3--10 NL of an isoelectric focusing system (EttanIPGphoreIII). Strips were rehydrated (20°C, 16 h) and isoelectric focused (500 volts for 500 volt-h, 1,000 volts for 800 volt-h, and 10,000 volts to reach 36,000 volt-h). The maximum current was maintained at 75 *μ*A per strip. Strips were subsequently equilibrated twice (15 min each) in equilibration buffer (50 mM Tris pH 8.8, 6 M urea, 30% glycerol, 2% SDS, and 0.03% bromophenol blue) supplemented with 65 mM DTT and 135 mM iodoacetamide. The strips were subjected to the second dimensional separation (Ettan DALTsix) using a SDS-polyacrylamide gel (12.5%) run under an applied voltage of 10 watts per gel at 20°C until the bromophenol blue dye front reached 0.5 cm from the bottom of the gel. The gels were subsequently stained with colloidal Coomassie blue. Spots identified as differentially regulated were removed from the blot and subjected to "in-gel" tryptic digestion as described previously \[[@B23]\]. Peptides were identified by LC-MS/MS using a Dionex Ultimate 3000 (Thermo Scientific) in combination with an electrospray ionization (ESI)/quadrupole ion trap mass spectrometer (amaZon SL, Bruker Daltonik, Germany). The LC separation was performed on a reverse phase column (Hypersil GoLD 50 × 0.5 mm, 5 *μ*m C18), protected by a guard column, and eluted at a flow rate of 100 *μ*L/min under gradient conditions of 5--80%B over 50 min. The mobile phase A consisted of water/formic acid (99.9 : 0.1, v/v), and mobile phase B consists of acetonitrile (100, v). Mass spectral data from 150 to 1500*m/z* was collected in the positive ionization mode. The MS/MS spectrometry data were searched against the NCBInr database using the MASCOT search engine as described previously \[[@B22], [@B23]\].

### 2.1.5. Protein Preparation and Western Blotting {#sec2.1.5}

Sera were individually albumin depleted as above and concentrated using a Vivaspin 2 ultrafiltration column with a 10 kDa molecular weight cut-off (GE Healthcare, Buckinghamshire, UK) according to the manufacturer\'s recommendations. Protein concentration then was determined as before and samples were stored at −80°C until required. SDS-PAGE and Western blot analysis were employed to determine the enrichment of serum. Approximately 50 *μ*g proteins were subjected to electrophoresis on 10% SDS-polyacrylamide gels and transferred to PVDF solid matrix support (Amersham Hybond-P, GE Healthcare) and analyzed as previously described \[[@B23]\]. The primary antibodies used were anti-RhoBTB3 (Sigma-Aldrich Co., St. Louis, MO), anti-ZIP kinase antibody (DAPK3) (Abcam plc, Cambridge, UK), anti-haptoglobin (Abcam plc), anti-transferrin (Abcam plc), and anti-GAPDH (Cell Signaling Technology, Inc., Danvers, MA). The secondary antibodies used were a goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology Inc., Santa Cruz, CA) and a goat anti-mouse IgG-peroxidase (Sigma-Aldrich, Milwaukee, WI). Blots were visualized using Luminata Forte Western HRP Substrate (Merck KGaA, Darmstadt, Germany) detection system, according to the manufacturer\'s instructions. Antibodies against transferrin and/or GAPDH were employed as internal controls. Image J software was employed to determine optical density values of bands for relative comparisons. The experiment was performed in triplicate.

2.2. Statistical Analysis {#sec2.2}
-------------------------

The data were expressed as mean ± SD. To compare clinical parameters and the expression level of proteins among patients and control, statistical significance of bands intensity was determined using one-way ANOVA with Bonferroni\'s multiple comparison test using Prism 5. *P* values less than 0.05 were considered statistically significant.

3. Results {#sec3}
==========

3.1. Study Participants and Clinical Parameters of Participants {#sec3.1}
---------------------------------------------------------------

Between June 22, 2012, and August 1, 2012, a total of 31 HIV/HCV and HIV adults were screened for enrollment in the study ([Figure 1](#fig1){ref-type="fig"}). A total of 11 patients (35.5%) were excluded due to the presence of normal ALT (1), negative anti-HCV (2), borderline ALT level (4), and a further 4 were not included in the analysis to give equal *N* values in the four patient groups. In addition, five healthy controls were recruited. All patients had had normal baseline ALT levels before commencement of NVP therapy. Based upon levels of ALT at the time of sample collection, patients were divided into four groups, HIV/HCV-coinfected patients with high ALT (group 1), HIV/HCV-coinfected patients with normal ALT (group 2), HIV-monoinfected patients with high ALT (group 3), HIV-monoinfected patients with normal ALT (group 4), and healthy controls represented a fifth group (Ctl). [Figure 2](#fig2){ref-type="fig"} shows the characteristics of each group for age, ALT, AST, period of using NVP, and CD4+ cell count. No significant difference was observed between all groups for age distribution, and similarly no difference was observed in the patient groups for the period of NVP usage. Group 1 had significantly higher ALT and AST levels than the control group as well as groups 2 and 4. Group 4 had a significantly higher mean CD4+ cell count than groups 1, 2, and 3.

3.2. Urine Proteomic Analysis {#sec3.2}
-----------------------------

Sub-10 kDa protein fractions prepared from pooled urine samples of the five groups were subjected to in-solution tryptic digestion followed by LC-MS/MS analysis. A total of 318 proteins were identified, of which 47 were differentially expressed between groups ([Table 1](#tab1){ref-type="table"}). The majority of differentially expressed proteins were identified as being involved in transcription (24%), signal transduction (13%), transport (11%), and immune responses (11%). The remaining proteins were associated with a range of diverse functions. Some 32% of the identified proteins were cytoplasmic, with 21% being membrane proteins and a further 24% were identified as nuclear proteins.

Of the 47 differentially expressed proteins, 33 were found in all groups while 14 proteins were identified only in some groups. Of the 14 proteins found in only some groups, seven (Sacsin, carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 3, KIAA0591 protein, metabotropic glutamate receptor 5 isoform b precursor, UBA3, vacuolar protein sorting-associated protein 45, and E3 ubiquitin-protein ligase HECTD1) were only found in patients groups and were absent from controls, although the level of the 7 proteins was similar between the patient groups (data not shown). The remaining 7 proteins showed no discernible trend for association with NVP treatment and liver damage.

3.3. Serum Proteomic Analysis: In-Solution {#sec3.3}
------------------------------------------

LC-MS/MS analysis of the sub-10 kDa fraction of pooled serum samples revealed a total of 251 identified proteins, of which 34 were found to be differentially expressed. Details of the 34 proteins and their biological function are presented in [Table 2](#tab2){ref-type="table"}. The majority of differentially expressed proteins were associated with transport (14%), cell development (12%), apoptosis (9%), cell adhesion (9%), lipid metabolism (9%), signal transduction (9%), and transcription (9%). The identified proteins were primarily identified as cytoplasmic (47%) and membrane proteins (20%).

Twenty-seven of the differentially expressed proteins were found in all groups. Seven proteins (Rho-related BTB domain containing protein 3 (RhoBTB3), zinc finger and BTB domain containing protein 44 (ZTBT44), obscurin isoform B, BAI 1, RNA exonuclease 1 homolog, death-associated protein kinase 3 (DAPK3), and chondroitin sulfate proteoglycan 4 protein (CSPG4)) showed restricted expression in 1 to 3 groups.

The peptide intensity analysis showed ([Table 3](#tab3){ref-type="table"}) that RhoBTB3 was detected only in the high ALT groups from both HIV/HCV coinfection and HIV monoinfection and was not detected in the normal ALT groups or in normal control samples. The peptide intensity in the HIV/HCV-coinfected group (group 1) was approximately double that found in the monoinfected group (group 3). DAPK3 and CSPG4 were both highly expressed in control and greatly reduced or absent in the patient groups. The remaining peptide intensity distributions were largely uninformative, and so RhoBTB3 and DAPK3 were selected for validation by Western blot analysis.

3.4. Serum Proteomic Analysis: In-Gel {#sec3.4}
-------------------------------------

Albumin depleted pooled serum samples from the five groups were subjected to 2D gel electrophoresis and the gels were stained with Coomassie blue (data not shown). Two spots were identified, one of which was only expressed in group 1 while the second was observed to be significantly downregulated in group 1 as compared to the other groups, including control. The two spots were excised from the gels, subjected to tryptic digestion, and the resultant peptides analyzed by LC-MS/MS. Resultant data was searched against the SwissProt database for protein identification using the Mascot software (<http://www.matrixscience.com/>). The proteins were identified as transthyretin and haptoglobin, respectively.

4. Validation of Serum Biomarkers Using Western Blotting {#sec4}
========================================================

From the results of the in-solution and in-gel proteomic analyses of serum, three proteins (DAPK3, RhoBTB3, and haptoglobin) were selected for confirmation by Western blotting analysis. Each of the 25 serum samples was individually albumin depleted and proteins were separated by electrophoresis before transfer to solid matrix support and Western blot analysis. Levels of GAPDH or transferrin were additionally determined as an internal control. Results showed that haptoglobin ([Figure 3](#fig3){ref-type="fig"}) was significantly reduced in group 1 (HIV/HCV-coinfected patients with high ALT). Levels of serum haptoglobin in group 4 (HIV-monoinfected patients with normal ALT) were similar to levels in the control group and significantly above the levels seen in the three remaining patients groups (HIV/HCV-coinfected patients with high ALT, HIV/HCV-coinfected patients with normal ALT, and HIV-monoinfected patients with high ALT). The largest difference in haptoglobin levels was seen between group 1 (HIV/HCV-coinfected patients with high ALT) and group 4 (HIV-monoinfected patients with normal ALT). While some slight differences were noted between the groups for both RhoBTB3 and DAPK3, the differences did not reach statistical significance.

5. Discussion {#sec5}
=============

A highly active antiretroviral treatment (HAART) regimen containing NVP appears to be associated with a higher risk for increased liver damage in HIV-1-infected patients who are coinfected with HCV as compared to monoinfected HIV patients, and as such specific biomarkers that can be used in conjunction with ALT would be useful as an adjunct marker to ALT alone. Towards this end, this study undertook a proteomic analysis of serum and urine from HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term NVP treatment in parallel with control samples.

The patient samples were analyzed in four groups, namely, HIV/HCV coinfection with high ALT (group 1), HIV/HCV coinfection with normal ALT (group 2), HIV monoinfection with high ALT (group 3), and HIV monoinfection with normal ALT (group 4). The patients in the high ALT cohorts all had grade 1 liver elevation except two patients in group 1 who had grade 2 elevation. No higher ALT grade patients were available as their regimes are normally altered to prevent further liver damage. As such, this study was somewhat limited in the range of liver hepatotoxicity studied and the study should be further cautiously interpreted in light of the small number of patients in each group.

A total of 83 proteins were identified through the three arms of the study (in-solution analysis of serum and urine and in-gel analysis of serum), although no protein was identified consistently in all three arms of the study, presumably as a result of differing sample and methodological approach. The two proteins selected for further validation from those identified from the in-solution proteomic analysis (RhoBTB3 and DAPK3) showed only slight and nonsignificant differences between the four patient groups. The third protein, haptoglobin, identified from the in-gel 2D electrophoresis assay showed slight but not statistically significant elevation in monoinfected HIV patients with normal ALT and statistically significantly reduced levels compared to normal controls in HIV/HCV-coinfected patients with high ALT. Levels of haptoglobin were slightly reduced in HIV/HCV-coinfected patients with high ALT (group 1) as compared to HIV/HCV-coinfected patients with normal ALT (group 2) although this was not statistically significant. However, as noted previously, the absence of grades 3 and 4 ALT levels probably reduces the discriminating ability of the analysis.

The plasma protein, haptoglobin, is synthesized by hepatocytes and functions to noncovalently bind oxidized hemoglobin generated by hemolysis \[[@B24]\]. The hemoglobin-haptoglobin complex is taken up by the reticuloendothelial system both to scavenge iron for recycling and to prevent adverse oxidative effects \[[@B24]\]. A significant decrease in haptoglobin levels during ART has been previously reported \[[@B25]\], and the decrease was unrelated to hemophilia or HCV status, and was not associated with the presence of increased markers of hemolysis. In our study, we observed a significant decrease in haptoglobin levels in patients with HIV/HCV coinfection and high ALT and nonsignificant reductions in patients with HIV/HCV coinfection and normal ALT and in monoinfected HIV patients with normal and high ALT. A significant difference was seen between levels of haptoglobin in monoinfected HIV patients with high and normal ALT, and while it did not reach statistical significance, the levels of haptoglobin were reduced in HIV/HCV-coinfected patients with high ALT as compared to HIV/HCV-coinfected patients with normal ALT. These results suggest that reduced levels of haptoglobin may reflect increased liver damage. In this regard, haptoglobin has previously been reported as a serum marker of fibrosis in chronic hepatitis C patients \[[@B26]\], where it is believed that liver fibrosis leads to increased expression of hepatocyte growth factor promoting a subsequent decrease in haptoglobin levels.

Studies have suggested that serum haptoglobin predicts liver fibrosis in hepatitis C patients where it was found that haptoglobin was one of the top candidate proteins for discriminating grade 0 from grades 1--4 liver fibrosis as well as discriminating grade 3 from grade 4 \[[@B27]\], while another study reported that haptoglobin serum levels were negatively correlated to scores of fibrosis (*P* \< 0.001) and suggested that determination of haptoglobin serum level may be useful in the follow-up of patients with chronic hepatitis C \[[@B28]\].

Although the patients in this project were not yet in fibrotic stages, a correlation between liver status and haptoglobin was observed in group 1 in comparison with group 2 HCV patients. The patients in group 1 have more severe grade 2 liver injury as compared to the patients in group 2 that contained only grade 1 liver injury and showed lower haptoglobin levels. However, this was not statistically significant, possibly since only two out of five patients in group 1 were grade 2 for liver injury. Interestingly, patient group 3 (monoinfected with HIV with high ALT) had relatively low level of haptoglobin compared to group 4 who had normal ALT suggesting that haptoglobin may be an earlier marker for liver injury caused by NVP in HIV patients. Haptoglobin is one of five parameters (alpha2-macroglobulin, haptoglobin, apolipoprotein A1, gamma glutamyl transpeptidase, and bilirubin) used to evaluate liver fibrosis stage in the Fibrotest \[[@B29]\] and an inverse relationship between haptoglobin and bilirubin levels have been reported in hepatitis patients although the relationship was dependent upon the type of liver disease \[[@B30]\].

Overall, this study identified a number of possible candidate biomarkers of NVP induced liver toxicity, one of which (haptoglobin) was successfully validated. Two potential biomarkers failed Western blot validation (RhoBTB3 and DAPK3) but remain of interest for possible future validation in larger cohorts of patients.
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![Schematic of patient inclusion and exclusion.](DM2014-315824.001){#fig1}

![Means ± SD of clinical parameters. The information was obtained from 5 HIV/HCV-coinfected patients with high ALT (G1), 5 HIV/HCV-coinfected patients with normal ALT (G2), 5 HIV-monoinfected patients with high ALT (G3), 5 HIV-monoinfected patients with normal ALT (G4), and 5 healthy controls (Ctl). ALT: alanine transaminase; AST: aspartate aminotransferase. All values are reported as means ± SD. One-way ANOVA with Bonferroni\'s multiple comparison test was performed; statistical significance is shown by \# for *P* \< 0.05.](DM2014-315824.002){#fig2}

![Western blot analysis and quantitation of haptoglobin expression in serum of normal controls and HIV patients undergoing long term NVP treatment. (a) Serum samples were individually depleted for albumin and proteins run as triplicate replicates before transfer to solid matrix support and western analysis to determine haptoglobin expression. Filters were reprobed after stripping with an antibody against transferrin to provide a loading control. G1 (group 1; HIV/HCV-coinfected patients with high ALT), G2 (group 2; HIV/HCV-coinfected patients with normal ALT), G3 (group 3; HIV-monoinfected patients with high ALT), G4 (group 4; HIV-monoinfected patients with normal ALT), and control (healthy controls). (b) Quantitation was determined by image analysis and is expressed as relative intensity (haptoglobin/transferrin). Data is plotted as means ± SD. Statistical significance was determined using one-way ANOVA with Bonferroni\'s multiple comparison test. \# designates *P* \< 0.05.](DM2014-315824.003){#fig3}

###### 

List of proteins detected as differentially regulated in urine of patients undergoing long term NVP treatment and normal controls.

  Protein name                                                                  Database ID number   Protein ID score   Function                  Localization   Mass (Da)   Peptide sequence
  ----------------------------------------------------------------------------- -------------------- ------------------ ------------------------- -------------- ----------- -------------------
  ADAMTS12                                                                      gi∣124297123         3.21               Protein metabolism        Unknown        1036.6585   KCNQQACK
  Sacsin                                                                        gi∣327200585         2.49               Immune response           Membrane       911.5248    FTSEVAXR
  NADPH oxidase                                                                 gi∣34810991          2.66               Immune response           Cytoplasm      722.5438    YTVVXK
  Ubiquitin-conjugating enzyme E2                                               gi∣269914374         2.24               Ubiquitin metabolism      Cytoplasm      849.2900    AGSMALKR
  Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 3   gi∣2289786           12.59              Transcription             Nucleus        672.2483    LPGAGEK
  dynein                                                                        gi∣119627741         4.40               Single                    Cytoplasm      733.7764    LFAQVR
  Dystroglycan                                                                  gi∣294997282         9.68               Cytoskeleton              Cytoplasm      679.6234    KPPLPK
  E3 ubiquitin-protein ligase HECTD1                                            gi∣118498337         22.38              Ubiquitin metabolism      Cytoplasm      870.7503    KASLALIR
  FL100154                                                                      gi∣18676514          6.78               Others                    Unknown        1532.2699   PEMTGVTVSGLTPAR
  hCG1783738                                                                    gi∣119606481         1.35               Others                    Unknown        756.2752    KPALGNR
  hCG2042782                                                                    gi∣119574283         5.61               Others                    Unknown        972.8246    VAMTVIKPV
  hCG2045758                                                                    gi∣119626212         5.75               Others                    Unknown        867.1841    RVASAYLS
  Protein HEG homolog 1                                                         gi∣33871486          8.09               Cell development          Membrane       850.1389    LFDLADR
  hydroxyacylglutathione hydrolase                                              gi∣119606016         3.62               Carbohydrate metabolism   Mitochondria   782.3398    VYGGDDR
  Hypothetical protein                                                          gi∣60219224          7.34               Others                    Unknown        1568.0209   DMQMGPGLFLRMR
  IgA nephropathy-related protein 1                                             gi∣307133516         5.16               Single                    Membrane       795.7409    GPVSPPNK
  Immunoglobulin heavy chain VHDJ region                                        gi∣21669823          1.48               Immune response           Cytoplasm      773.9408    RGGVGTTK
  Immunoglobulin kappa light chain                                              gi∣62860960          3.36               Immune response           Cytoplasm      920.3153    TVAAPSVFK
  Keratin                                                                       gi∣32567786          17.72              Cell development          Cytoplasm      701.4250    MDLHGK
  KIAA0591                                                                      gi∣29421178          4.69               Apoptosis                 Mitochondria   833.9171    SYTMMGK
  KIAA0895                                                                      gi∣4240279           5.22               Others                    Unknown        835.4904    DIGRFVK
  Patched domain containing protein                                             gi∣326205357         3.36               Transport                 Membrane       674.6955    LSKNGR
  KIAA1409                                                                      gi∣119601937         26.30              Response to stress        Membrane       856.7432    IAVSAIQR
  KIAA2010                                                                      gi∣24899184          1.10               Protein metabolism        Cytoplasm      902.6365    EDTLPLSK
  Metabotropic glutamate receptor 5                                             gi∣4504143           7.70               Single                    Nucleus        1406.2405   YEIMNFKEMGK
  MHC class 1 antigen                                                           gi∣123278215         7.54               Immune response           Membrane       688.0275    QAPTDR
  Myosin light chain kinase 2                                                   gi∣14043538          3.01               Transport                 Cytoplasm      1434.2871   DFVSNLIVKDQR
  Peroxisome proliferator-activated receptor alpha                              gi∣1514595           1.01               Transcription             Nucleus        758.7757    FDFAMK
  Progesterone-induced-blocking factor 1                                        gi∣3925685           6.64               Transcription             Cytoplasm      986.7480    QNSLIXKR
  Pleckstrin homology domain containing family A member 6                       gi∣37595548          2.93               Lipid metabolism          Cytoplasm      757.5746    SVPQAVR
  Poly(ADP-ribose) polymerase 1                                                 gi∣119590191         7.36               Transcription             Nucleus        1475.5247   LQGHVPQTSLQLR
  Suppressor of cytokine signaling 5                                            gi∣23273934          3.30               Single                    Cytoplasm      783.9406    RDSYSR
  REST corepressor                                                              gi∣344925845         5.18               Transcription             Nucleus        673.1253    GPEVSGK
  REST corepressor 3                                                            gi∣21595082          7.97               Transcription             Nucleus        714.2440    GPELLGK
  Uncharacterized protein FLJ37004                                              gi∣74729710          3.79               Others                    Unknown        1519.9062   ATAAAARGSEVSGEGGK
  Serine/threonine protein kinase RIO3                                          gi∣119621558         2.00               Transport                 Membrane       1263.2434   ENVGDGIGMDLK
  Serine/threonine protein kinase PLK4                                          gi∣2125814           2.52               Single                    Cytoplasm      866.4060    DRASFNR
  SEC14-like 4                                                                  gi∣119580300         7.04               Transport                 Membrane       819.6610    SSATLWR
  SH2 domain containing protein 3C                                              gi∣4704739           3.24               Single                    Membrane       658.6454    TAVGRR
  Sorting nexin-3                                                               gi∣3126979           2.35               Transport                 Membrane       1017.4337   AETVADTRR
  NEDD8-activating enzyme E1 catalytic subunit                                  gi∣3342564           1.45               Transcription             Nucleus        744.0996    LTQGVVK
  Uncharacterized protein                                                       gi∣254692913         2.93               Others                    Unknown        1000.3987   RLLNELDK
  Ribosomal RNA upstream binding transcription factor                           gi∣1916615           2.03               Transcription             Nucleus        780.6412    LRGPNPK
  Vacuolar protein sorting-associated protein 45                                gi∣18105063          5.13               Transcription             Nucleus        838.4481    KMSGTVSK
  WD repeat-containing protein 46                                               gi∣256773176         7.41               Transcription             Nucleus        696.2765    KPQVPK
  Coiled-coil domain containing protein 105                                     gi∣226492892         2.14               Transcription             Nucleus        540.5465    APTPR
  17-*beta*-Hydroxysteroid dehydrogenase 14                                     gi∣59889578          7.76               Cell division             Cytoplasm      506.0660    ATGTR

###### 

List of proteins detected as differentially regulated in serum of patients undergoing long term NVP treatment and normal controls.

  Protein name                                                          Database ID number   Protein ID score   Function                  Localization   Mass (Da)   Peptide sequence
  --------------------------------------------------------------------- -------------------- ------------------ ------------------------- -------------- ----------- ------------------
  BAI 1                                                                 gi∣2653432           10.04              Cell adhesion             Membrane       857.1950    NATGLILR
  BCL2/adenovirus E1B 19 kDa interacting protein                        gi∣119573869         2.14               Apoptosis                 Nucleus        878.1002    VFRMGPR
  Catenin alpha-1                                                       gi∣21411495          6.22               Cell adhesion             Cytoplasm      1492.7295   EYAQVFREHANK
  Death-associated protein kinase 3                                     gi∣4557511           1.79               Apoptosis                 Cytoplasm      617.4699    QKGTGK
  Zinc finger protein 174                                               gi∣159163639         7.90               Transcription             Nucleus        742.0348    CLMSSK
  Collagen type X11 alpha-1                                             gi∣1846005           15.77              Cell adhesion             Unknown        1554.9274   GGNTMTGDAIDYLVK
  Corin                                                                 gi∣4884872           2.91               Protein metabolism        Membrane       1474.3988   WVLTVAHCFEGR
  Chondroitin sulfate proteoglycan 4                                    gi∣124504610         3.64               Carbohydrate metabolism   Membrane       1551.0338   TGKHDVQVLTAKPR
  FYVE and coiled domain containing protein 1                           gi∣13276231          4.84               Transport                 Cytoplasm      874.5961    AALDDQDK
  hCG1811779                                                            gi∣119578948         2.12               Others                    Unknown        701.1700    LTGPAGGK
  hCG2018146                                                            gi∣119595992         1.36               Others                    Unknown        815.1358    CLLRPR
  hCG2033821                                                            gi∣119618839         2.35               Others                    Unknown        707.6396    TATEMR
  Obscurin isoform B                                                    gi∣89143259          1.77               Apoptosis                 Cytoplasm      1002.3102   KKPGLASFR
  Eukaryotic translation initiation factor 4B                           gi∣48146033          3.18               Translation               Cytoplasm      828.0649    EPSNPER
  Coiled-coil domain containing 146                                     gi∣23271918          4.84               Cytoskeleton              Cytoplasm      955.2563    ELVVNLLR
  Sodium dependent glucose transporter 1                                gi∣154937330         5.29               Transport                 Membrane       982.5936    HLPETRTK
  Microtubule associated protein 1a                                     gi∣1790878           2.47               Cytoskeleton              Cytoplasm      849.2162    DKDLEXK
  Myosin VI                                                             gi∣9280816           1.43               Cell development          Cytoplasm      519.0438    AAAGTK
  Peroxisomal *trans*-2-enoyl-coA reductase                             gi∣19923817          7.82               Lipid metabolism          Cytoplasm      846.0755    GAGDLSVVK
  Phospholipase B domain containing protein 1                           gi∣15029600          3.14               Lipid metabolism          Cytoplasm      927.4162    MMADSGKR
  Calmodulin-regulated spectrin-associated protein 2                    gi∣44955929          20.38              Cytoskeleton              Cytoplasm      701.6011    AGSLILK
  C-type lectin domain family 4 member K                                gi∣305410858         12.79              Immune response           Cytoplasm      702.7117    ASALNTK
  Zinc finger and BTB domain containing protein 44                      gi∣30047807          20.92              Transcription             Nucleus        905.7966    VQDKIFR
  RNA exonuclease 1 homolog                                             gi∣145199237         10.68              DNA replication           Nucleus        821.9409    ASSRDER
  Rhesus blood group D antigen                                          gi∣28629452          6.69               Transport                 Membrane       691.7388    VVITLF
  Rho-related BTB domain containing 3                                   gi∣27371219          5.84               Singal                    Membrane       1897.7174   CEVMAAMFNGNYMEAK
  Solute carrier family 4, sodium bicarbonate cotransporter, member 5   gi∣119620095         24.26              Transport                 Membrane       856.6955    SPSSLLPR
  Tyrosine-protein phosphate non receptor type 23                       gi∣24308073          3.39               Single                    Cytoplasm      1008.7161   HVEQVLQR
  Zinc finger protein 556                                               gi∣13376460          4.83               Transcription             Nucleus        710.6905    CGKCGK
  Dynactin 1                                                            gi∣4139121           3.52               Transport                 Cytoplasm      515.6265    APTAR
  Casein kinase I isoform gamma-1                                       gi∣98986450          7.18               Single                    Cytoplasm      685.1477    HIPYR
  hCG2045456                                                            gi∣119605796         2.79               Others                    Unknown        671.2872    EFNNF
  Group IIF secretory phospholipase A2                                  gi∣145553989         3.89               Lipid metabolism          Cytoplasm      462.4213    ADGAK
  hCG2038093                                                            gi∣119602010         3.27               Others                    Unknown        613.7015    HVSRD

###### 

Peptide intensities of 7 proteins showing differential expression of serum proteins between groups.

  Protein                     Group 1   Group 2   Group 3   Group 4   Control
  --------------------------- --------- --------- --------- --------- ---------
  RhoBTB3                     20.03     0         9.20      0         0
  ZTBT44                      0         5.49      8.48      16.72     0
  Obscurin isoform B          17.40     5.76      3.58      0         28.70
  BAI 1                       17.30     4.69      1.60      0         28.86
  RNA exonuclease 1 homolog   19.05     0         9.10      16.11     29.70
  DAPK3                       0         7.61      10.61     14.59     30.44
  CSPG4                       0         6.15      0         12.80     30.66

Group 1: HIV/HCV-coinfected patients with high ALT; Group 2: HIV/HCV-coinfected patients with normal ALT; Group 3: HIV-monoinfected patients with high ALT; Group 4: HIV-monoinfected patients with normal ALT; Control: healthy controls. Seven proteins RhoBTB3: Rho-related BTB domain containing protein 3; ZTBT44: zinc finger and BTB domain containing protein 44; DAPK3: death-associated protein kinase 3; CSPG4: chondroitin sulfate proteoglycan 4. Peptide intensity values are shown to 2 decimal places.

[^1]: Academic Editor: Robert Pichler
